Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer
    Meeting Abstract

    Vergote, I.; Perez-Fidalgo, J. A.; Hamilton, E. P.; Van Gorp, T.; Valabrega, G.; Laenen, A.; Oza, A. M.; Levy, T.; Cibula, D.; Sehouli, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)
    Meeting Abstract

    Kwan, T.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A. P.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
    Meeting Abstract

    Bachet, J. B.; Chibaudel, B.; Rakez, M.; Goldberg, R. M.; Tebbutt, N. C.; Van Cutsem, E.; Haller, D. G.; Hecht, J. R. R.; Mayer, R. J.; Lichtman, S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Grisham, R. N.; Vergote, I.; Banerjee, S. N.; Drill, E. N.; Fabbro, M.; Mirza, M. R.; Romero, I.; Coleman, R. L.; Oza, A. M.; Hilpert, F.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC)
    Meeting Abstract

    Lorusso, D.; Colombo, N.; Herraez, A. C.; Santin, A.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors - Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort
    Meeting Abstract

    Hamilton, E. P.; Jackson, C. C.; Eskander, R. N.; Backes, F. J.; Makker, V.; Musa, F.; Olawaiye, A.; Alldredge, J.; Pothuri, B.; Secord, A. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; O'Kane, G. M.; Goto, K.; Kim, D. W.; Neuzillet, C.; Martin-Romano, P.; Duruisseaux, M.; Nagasaka, M.; Rodon, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Monk, B. J.; Van Nieuwenhuysen, E.; Moore, K. N.; Oaknin, A.; Fabbro, M.; Colombo, N.; O'Malley, D. M.; Coleman, R. L.; Pachter, J. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies
    Meeting Abstract

    Schram, A. M.; Ahnert, J. R.; Patel, M. R.; Jauhari, S.; Sachdev, J. C.; Zhu, V. W.; LoRusso, P.; Nguyen, D.; Le, X.; O'Connor, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study
    Meeting Abstract

    Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Liu, Y. L.; Provencher, D. M.; McCormick, C.; ElNaggar, A.; Altman, A. D.; Gilbert, L.; Black, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save